Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.30% | 10.73% | 8.96% | 9.80% | 14.82% |
| Total Other Revenue | 18.94% | 15.16% | 7.64% | 6.14% | 3.36% |
| Total Revenue | 11.50% | 10.85% | 8.92% | 9.70% | 14.48% |
| Cost of Revenue | 6.79% | 6.66% | -1.07% | -0.09% | 16.23% |
| Gross Profit | 13.10% | 12.30% | 12.54% | 13.29% | 13.90% |
| SG&A Expenses | 2.75% | 0.59% | 2.23% | 3.20% | 7.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -8.10% | 16.79% | 71.86% | 218.95% | -56.90% |
| Total Operating Expenses | 5.72% | 4.80% | -7.40% | 2.12% | 7.70% |
| Operating Income | 25.38% | 26.99% | 57.48% | 30.75% | 34.88% |
| Income Before Tax | 53.29% | 49.51% | 53.12% | 30.53% | 38.47% |
| Income Tax Expenses | 230.87% | 208.71% | -8.54% | -36.60% | -40.65% |
| Earnings from Continuing Operations | 41.16% | 39.28% | 62.19% | 42.73% | 52.34% |
| Earnings from Discontinued Operations | -- | -- | 888.49% | 939.59% | 1,036.67% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 66.67% | 150.00% | 200.00% | 50.00% | 25.00% |
| Net Income | -15.65% | -19.59% | 124.64% | 111.49% | 116.98% |
| EBIT | 25.38% | 26.99% | 57.48% | 30.75% | 34.88% |
| EBITDA | 12.18% | 11.00% | 36.28% | 19.11% | 22.94% |
| EPS Basic | -13.28% | -17.72% | 130.92% | 118.87% | 126.73% |
| Normalized Basic EPS | 29.86% | 29.60% | 65.40% | 36.61% | 42.06% |
| EPS Diluted | -13.39% | -17.71% | 130.18% | 118.38% | 126.83% |
| Normalized Diluted EPS | 29.81% | 29.50% | 65.49% | 36.71% | 42.27% |
| Average Basic Shares Outstanding | -2.90% | -2.76% | -3.01% | -3.62% | -4.47% |
| Average Diluted Shares Outstanding | -2.83% | -2.66% | -3.01% | -3.64% | -4.51% |
| Dividend Per Share | -1.44% | -1.44% | 13.24% | 13.24% | 13.24% |
| Payout Ratio | 0.76% | 0.31% | -0.53% | -0.50% | -0.67% |